Connect with us

Press Release

Luxury Glass Tinting Sets New Standard in Vehicle Care with Advanced Paint Protection Film

Published

4 hours ago

on

This advanced technology, often referred to as Clear Bra, creates an invisible shield against scratches, chips, stains, and sun damage, redefining the way drivers can protect their vehicles from everyday hazards.

California, US, 27th September 2025, ZEX PR WIRE, Los Angeles presents unique challenges for car owners who care about appearance. Congested highways, constant exposure to sunlight, tree-lined streets, and crowded parking lots all contribute to wear that diminishes both the look and the value of a vehicle.

“By shielding the original paint, PPF preserves the long-term market value of cars, whether they are luxury sedans, sports cars, SUVs, or daily commuters. For owners who view their vehicles as investments, the service offers a practical way to safeguard both beauty and value over time.”

Luxury Glass Tinting’s Paint Protection Film is engineered to address these realities, using high-performance materials that form a resilient layer over a car’s exterior without changing its design or finish. The result is long-lasting protection that allows vehicles to look newer for longer while reducing the need for frequent detailing or costly paint repairs.

Paint Protection Film stands out because it is not only durable but also virtually invisible. Drivers can maintain the original shine, color, and design of their cars while gaining protection against rock chips, bird droppings, gravel, tree sap, and other daily threats. Unlike aftermarket wraps or coatings that may dull a car’s appearance, Luxury Glass Tinting’s films enhance a vehicle’s finish and provide lasting clarity, ensuring the original paintwork remains untouched.

The innovation extends beyond surface-level defense. Modern Paint Protection Films now include self-healing technology, allowing minor scratches and swirl marks to fade when exposed to heat from sunlight or warm water. This feature ensures that vehicles maintain a polished look even after years of use. Additionally, the hydrophobic nature of the film repels water, dirt, and grime, meaning cars stay cleaner for longer and are easier to maintain. For Los Angeles drivers battling dusty streets and frequent freeways, the convenience of low-maintenance protection offers immediate appeal.

Luxury Glass Tinting understands that drivers have diverse needs and preferences, which is why the company offers multiple options. “Clear films provide nearly invisible protection that preserves factory paint. Matte finishes deliver a modern, understated style while maintaining the same level of resilience. For those looking to stand out, custom designs with unique patterns or accents are also available,” shared a representative from the company.

Unlike lower quality applications that often bubble, wrinkle, or peel under stress, Luxury Glass Tinting’s Paint Protection Film is engineered for long-term durability. The company employs advanced heat tools, precision cutting systems, and a panel-by-panel approach that guarantees an exact fit on each vehicle. Every installation is followed by a meticulous inspection to ensure seamless adhesion and a finish that is virtually undetectable. This emphasis on detail reflects the company’s philosophy that no project is complete until it meets their exacting standards.

To cater to the diverse preferences of Los Angeles drivers, Luxury Glass Tinting offers multiple styles of Paint Protection Film. The clear option remains the most popular, providing invisible defense while allowing the factory paint to shine through. Drivers seeking a bolder look can choose matte finishes that give vehicles a modern, refined appearance without sacrificing durability. For those who want to combine style with protection, custom patterns, logos, and accents can be integrated into the film. The company also offers top-coated options that provide even greater resilience against scratches and abrasions, ideal for drivers who face harsher road environments.

Luxury Glass Tinting has expanded its services with Paint Protection Film, meeting the rising demand for durable, low-maintenance solutions that preserve vehicle appearance and performance. As more drivers keep their cars longer and invest in their upkeep, this technology has become a must-have for those who value both protection and style.

Known in Los Angeles for blending advanced technology, skilled craftsmanship, and customer care, Luxury Glass Tinting now offers a comprehensive suite of solutions—from window tinting to solar control films and paint protection. Drivers can explore this innovation through complimentary consultations and customized installation plans, further cementing the company’s reputation as a leader in automotive surface care.

About Luxury Glass Tinting

Luxury Glass Tinting is a premier provider of advanced window tinting and vehicle protection solutions in Los Angeles. Known for precision craftsmanship and superior customer service, the company specializes in automotive, residential, commercial, decorative, marine tinting, and paint protection film installations. By combining cutting-edge technology with expert application, Luxury Glass Tinting delivers results that enhance comfort, style, and long-term value. With a reputation built on quality and trust, the company continues to set new standards in vehicle care and surface protection across Southern California

Contact

Website: www.luxuryglasstinting.com
Address 1: 11379 Playa Street, Culver City, CA 90230
Address 2: 3950 W 8th St., Suite 402, Los Angeles, CA 90005
Phone: 310-925-0780 / 818-297-4963

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Yintai Tech Unveils Multi-Agent Collective Evolution Mechanism, Enabling an Ecosystem of Co-Evolving AI Agents

Published

34 minutes ago

on

September 28, 2025

By

[September 27, 2025] – While most multi-agent platforms in the industry still focus on “parallel collaboration,” Yintai Tech today officially announced its pioneering “Multi-Agent Collective Evolution Mechanism.” This breakthrough enables AI agents not only to collaborate but also to learn from and improve each other. Powered by Yintai’s self-developed “Yintai AIOS,” this mechanism fundamentally breaks down “experience silos,” allowing individual advancements to drive collective iteration and truly usher the agent ecosystem into an era of “co-evolution.”
 

Transcending Human Learning Limitations: A New Paradigm for Efficient Agent Evolution

Unlike human learning, which is often constrained by inherent bottlenecks in mode, speed, and success rate, the Agent collective learning mechanism driven by Yintai AIOS demonstrates significant advantages:
  • Precision Learning: From Ambiguous Transfer to Accurate Reuse Human knowledge transfer relies on language, suffering from degradation through the stages of summarization, expression, comprehension, and practice. In contrast, AIOS utilizes “capability decomposition and identification” to standardize superior agent capabilities (e.g., effective customer service dialogue) into plug-and-play modules (e.g., intent recognition, response generation). Other agents can precisely call and combine these modules like building blocks, drastically reducing the ambiguity of experience reuse.
  • Rapid Assimilation: From Years to Seconds Training human experts takes years, whereas within the AIOS ecosystem, once a single agent achieves a key capability breakthrough (e.g., precise public opinion analysis, efficient inventory forecasting), this capability can be instantaneously shared across the entire population. Other agents can learn and adapt within seconds, completely moving beyond the era of starting from scratch.
  • Guaranteed Mastery: From Innate Talent to 100% Replication of Best Practices AIOS automatically screens and evaluates verified “optimal capability modules” within the ecosystem, ensuring every agent accesses the “best possible answer.” Standardized modules and precise identification guarantee consistent learning outcomes, enabling all agents to “learn effectively the first time” and flexibly enhance their own capabilities.

 

A Three-Layer Technical Architecture Paving the Way for Collective Evolution

The “Multi-Agent Collective Evolution Mechanism” of Yintai AIOS is built upon a rigorous three-layer technical architecture, ensuring a complete closed loop from capability decomposition and evaluation to shared learning:
  • Capability Modularization & Registration Protocol: Decomposes complex capabilities into standard modules and registers them as callable “services” (Capability-as-a-Service) via a unified protocol, breaking down capability barriers and avoiding redundant development.
  • Multi-Dimensional Capability Evaluation & Knowledge Graph: An built-in evaluation engine scores modules based on dimensions like accuracy, efficiency, and robustness. This data populates a globally visible “Capability Knowledge Graph,” ensuring the system can automatically identify and recommend best-practice modules.
  • Collective Learning & Dynamic Migration Mechanism: Utilizes intelligent matching, parameter migration, and structural alignment technologies, orchestrated uniformly by the LangGraph+AIOS scheduler, to enable low-loss, secure, and controllable rapid experience transfer, strictly adhering to privacy rules and developer authorization.
 
This architecture also endows the collective evolution mechanism with three core advantages: standardized interfaces eliminate compatibility barriers, a dynamic evolution mechanism prevents capability stagnation, and a controlled sharing strategy balances openness with intellectual property protection, laying a solid foundation for sustainable ecosystem development.
 

Unlocking Value Across Three Layers, Driving Exponential Growth of the AI Ecosystem

The implementation of Yintai AIOS delivers tangible value to the industry across three layers:
  • Development Layer: Small and medium-sized developers can directly reuse “best-practice modules” from the ecosystem to rapidly build high-capability AI agents, significantly reducing development costs and technical barriers.
  • Application Layer: Enterprises can avoid building complex systems from the ground up. By flexibly combining mature capabilities within the ecosystem, they can quickly deploy AI solutions, accelerating implementation pace and reducing trial-and-error costs.
  • Ecosystem Layer: A virtuous cycle forms: “More agents → Richer capabilities → Faster ecosystem evolution.” This drives sustainable, exponential growth for the entire AI ecosystem.
 

Redefining Capability Inheritance: Towards a New Era of Human-AI Co-evolution

Mr. Mu Peng, Founder and CEO of Yintai Tech, stated, “The progress of human society stems from the sharing of individual experience and the iteration of collective wisdom. What we aim to build is not merely a multi-agent collaboration platform, but an AI ecosystem akin to human society – where the growth of every Agent propels the evolution of the whole, ultimately making AI technology a true ‘infrastructure’ driving the continuous advancement of human society.”
 
The Multi-Agent Collective Evolution Mechanism represents not only a significant technological breakthrough but also a paradigm shift in knowledge inheritance. It transcends the traditional model reliant on human effort, language, and slow-paced practice that has persisted for millennia, enabling intelligent systems to achieve “lossless, cross-domain, real-time” capability sharing. Just as the printing press expanded knowledge dissemination and the internet redefined information connectivity, Yintai Tech anticipates this mechanism will redefine the very way “capability” is created and inherited, heralding a new epoch where AI and humanity co-evolve, and capability dances with imagination.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

AsterINU Token Takes a Flying Start Blending Crypto Utility with Meme Culture through Seamless Cross-Chain Connectivity

Published

3 hours ago

on

September 28, 2025

By

LONDON, UK ACCESS Newswire  AsterINU, the community-driven meme token offering seamless cross-chain connectivity, made a successful debut on Dexscreen. Since AsterINU became available on Sept 22nd, the token has experienced a dramatic rise in both price and trading volume, highlighting its rapid growth and increasing relevance in the crypto ecosystem.

AsterINU is more than just a meme token. By blending crypto utility with meme culture, it aims to reflect Aster’s broader mission of fostering cross-chain interoperability. The project emphasizes community participation while offering investors exposure to a fast-moving, utility-inspired ecosystem.

Investors can easily purchase AsterINU through DEXTools and DEXTswap, particularly on the AsterINU/WBNB pool page, a trusted trading hub known for its speed and security. To buy, users simply connect their wallet via MetaMask, enter the desired amount of AsterINU, sign approval, and complete the swap.

The AsterINU smart contract address on the BNB chain is:

0x9f6c24232f1bba6ef47bcb81b9b9434acdb94444

The AsterINU/WBNB pair contract address is:

0xf5fda86bb33e46716dfcd845b2a78dff1e24567a

For convenience, purchasing options are also available through the official community channel: Buy at AsterINU Telegram

The AsterINU project is powered by its community-first approach, encouraging active participation and ongoing engagement. Through social channels and live updates, the token is building a movement that merges internet meme culture with serious crypto utility.

Follow AsterINU for the latest updates:

About AsterINU

AsterINU is a community-driven meme token inspired by Aster’s mission of enabling seamless cross-chain connectivity. By bridging crypto utility with the viral power of meme culture, AsterINU is positioning itself as both an entertaining and functional digital asset. Its strong trading momentum, transparent distribution, and rapidly growing community highlight its potential as a rising force in decentralized finance.

Contact person: Dave Aston

Company name: Aster inu

Website: https://asterinu.xyz/

Email: contact@asterinu.xyz

SOURCE: AsterINU

View the original press release on ACCESS Newswire

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

Published

15 hours ago

on

September 28, 2025

By

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the “Trial”) of ruxolitinib cream (the “Product”) in patients with mild to moderate atopic dermatitis (AD) in China.

The Trial is a randomized, double-blind, placebo-controlled, multi-centre clinical trial, with 192 patients enrolled in total, aiming to evaluate the safety and efficacy of the Product in patients with mild to moderate AD. The leading institution is Shanghai Dermatology Hospital, and the principal investigator is Professor Shi Yuling.

The phase 3 clinical trial of ruxolitinib cream in patients with mild to moderate AD in China met its primary endpoint, demonstrating that a significantly higher proportion of patients treated with ruxolitinib cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P<0.001). For the key secondary endpoint, the proportion of patients achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib cream was also significantly higher than placebo, at week 8 (78.0% vs 15.4%, P<0.001). In terms of safety, the severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, the ruxolitinib cream was safe and well-tolerated.

CMS is actively moving forward the Product’s new drug application (NDA) in China.

About AD

AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there are over 54 million AD patients in China by 2024. Based on SCORAD scores, the proportions of mild, moderate, and severe AD in China in 2024 was 73%, 25%, and 2%, respectively[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.

About Ruxolitinib Cream

Ruxolitinib cream (Opzelura®) is a novel cream formulation made of selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte (NASDAQ: INCY), which is the first topical JAK inhibitor approved for use in the United States by the U.S. Food and Drug Administration (FDA)[2]. Ruxolitinib cream is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older and for the topical short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The Product is also approved in Europe for the treatment of adolescents and adults from 12 years of age with non-segmental vitiligo with facial involvement.

The NDA for vitiligo indication of the Product has been accepted by the National Medical Products Administration of China (NMPA). Furthermore, the marketing authorization application have been approved in Hong Kong Special Administrative Region and Macau Special Administrative Region, and the Product was approved by the Guangdong Provincial Medical Products Administration through the “Hong Kong and Macau Medicine and Equipment Connect” policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.

CMS, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to CMS (excluding Dermavon and its subsidiary).

Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in Southeast Asia and the Middle East regions, further escorting the sustainable and healthy development.

References:

  1. China Insights Consultancy’s industrial report
  2. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us